OmniComm Systems Celebrates 10 Years of European Headquarters
FORT LAUDERDALE, FL, July 27, 2017 (GLOBE NEWSWIRE) - OmniComm Systems, Inc., a global provider of clinical data management technology, announced the 10-year anniversary of OmniComm Europe GmbH, the European headquarters of the parent company.
Earlier this year, OmniComm Systems-launched in Florida during early 1997-celebrated 20 years of growth and innovation. The company has gained a greater foothold in Europe and Asia in recent years, comprising approximately 20% of its annual revenue, in large part due to the local support from its European headquarters and additional European and Asian offices.
From its launch in July 2007, OmniComm Europe GmbH has grown from a staff of two people in Bonn, Germany to a team of 18 with more than 210 years of combined industry experience. The European headquarters offer expertise in clinical operations, EDC trial build, quality assurance, development, customized solutions, and a multi-lingual helpdesk and training services. OmniComm has additional European offices in the United Kingdom, The Netherlands, and Spain.
“We are very excited about our 10-year track record of organic growth and continuous expansion of our market presence in the region,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH. “We have achieved this milestone through the hard work of our team of industry professionals, who are passionate about delivering exceptional service and support. Seeing the trustful and long-lasting relationships with our clients and partners is a moment of pride and satisfaction for the entire team.”
OmniComm Europe GmbH mainly serves European clients, but also U.S.- and Asia-based trials with international investigative sites. Clients include biopharma and medical device companies, CROs, and academic medical centers.
“We are extremely pleased with the recent success we’ve had across all of our product lines internationally,” said Stephen Johnson, president and CEO of OmniComm Systems. “We’ve experienced a steady 25% compound annual growth rate (CAGR) over the last 10 years. Sales in Europe have doubled in the last two years alone.”
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
